CRMD Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 10.59%. CorMedix, Inc.'s return on equity of 95.25% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.

CorMedix, Inc. has a consensus price target of $19.00, signalling upside risk potential of 84.11%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.88 which suggests that it could grow by 32.91%. Given that CorMedix, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than ANI Pharmaceuticals, Inc..

CorMedix, Inc. has a beta of 1.322, which suggesting that the stock is 32.155% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CorMedix, Inc. quarterly revenues are $104.3M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. CorMedix, Inc.'s net income of $108.6M is higher than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, CorMedix, Inc.'s price-to-earnings ratio is 5.03x while ANI Pharmaceuticals, Inc.'s PE ratio is 50.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 3.47x versus 2.02x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kiniksa Pharmaceuticals International Plc has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 10.19%. CorMedix, Inc.'s return on equity of 95.25% beat Kiniksa Pharmaceuticals International Plc's return on equity of 7.6%.

CorMedix, Inc. has a consensus price target of $19.00, signalling upside risk potential of 84.11%. On the other hand Kiniksa Pharmaceuticals International Plc has an analysts' consensus of $54.00 which suggests that it could grow by 33.04%. Given that CorMedix, Inc. has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe CorMedix, Inc. is more attractive than Kiniksa Pharmaceuticals International Plc.

CorMedix, Inc. has a beta of 1.322, which suggesting that the stock is 32.155% more volatile than S&P 500. In comparison Kiniksa Pharmaceuticals International Plc has a beta of 0.017, suggesting its less volatile than the S&P 500 by 98.312%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiniksa Pharmaceuticals International Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Kiniksa Pharmaceuticals International Plc pays out -- of its earnings as a dividend.

CorMedix, Inc. quarterly revenues are $104.3M, which are smaller than Kiniksa Pharmaceuticals International Plc quarterly revenues of $180.9M. CorMedix, Inc.'s net income of $108.6M is higher than Kiniksa Pharmaceuticals International Plc's net income of $18.4M. Notably, CorMedix, Inc.'s price-to-earnings ratio is 5.03x while Kiniksa Pharmaceuticals International Plc's PE ratio is 90.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 3.47x versus 5.20x for Kiniksa Pharmaceuticals International Plc. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 21.32%. CorMedix, Inc.'s return on equity of 95.25% beat Pfizer Inc.'s return on equity of 10.84%.

CorMedix, Inc. has a consensus price target of $19.00, signalling upside risk potential of 84.11%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that CorMedix, Inc. has higher upside potential than Pfizer Inc., analysts believe CorMedix, Inc. is more attractive than Pfizer Inc..

CorMedix, Inc. has a beta of 1.322, which suggesting that the stock is 32.155% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

CorMedix, Inc. quarterly revenues are $104.3M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. CorMedix, Inc.'s net income of $108.6M is lower than Pfizer Inc.'s net income of $3.6B. Notably, CorMedix, Inc.'s price-to-earnings ratio is 5.03x while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 3.47x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Talphera, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of -443600%. CorMedix, Inc.'s return on equity of 95.25% beat Talphera, Inc.'s return on equity of -127.04%.

CorMedix, Inc. has a consensus price target of $19.00, signalling upside risk potential of 84.11%. On the other hand Talphera, Inc. has an analysts' consensus of $3.25 which suggests that it could grow by 150%. Given that Talphera, Inc. has higher upside potential than CorMedix, Inc., analysts believe Talphera, Inc. is more attractive than CorMedix, Inc..

CorMedix, Inc. has a beta of 1.322, which suggesting that the stock is 32.155% more volatile than S&P 500. In comparison Talphera, Inc. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.207%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Talphera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Talphera, Inc. pays out -- of its earnings as a dividend.

CorMedix, Inc. quarterly revenues are $104.3M, which are larger than Talphera, Inc. quarterly revenues of $1K. CorMedix, Inc.'s net income of $108.6M is higher than Talphera, Inc.'s net income of -$4.4M. Notably, CorMedix, Inc.'s price-to-earnings ratio is 5.03x while Talphera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 3.47x versus 1,491.40x for Talphera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.